Microbial metabolite as icebreaker for immunotherapy.
Level V
Where this comes from
- Record sourced from PubMed, PMID 35385701.
- Also identified by DOI 10.1016/j.cmet.2022.03.003.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immunotherapy has limited success in triple-negative breast cancer (TNBC). In this issue of Cell Metabolism, Wang et al. found that microbial metabolite TMAO boosts CD8<sup>+</sup> T cell-mediated antitumor immunity by inducing pyroptosis in tumor cells, enhancing the efficacy of immunotherapy in TNBC (Wang et al., 2022).
Medical subject headings
- Triple Negative Breast Neoplasms